Association of Obesity and Cardiovascular Outcomes in Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

56272 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, the investigators evaluated the association between various measures of adiposity \[BMI and waist circumference (WC)\] and clinical outcomes in Asian patients with AF who were prescribed OAC, using a nationwide population based cohort.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Association of Obesity and Cardiovascular Outcomes in Myocardial Infarction

NCT05645926

Obesity Associated Disorder Myocardial Infarction

UNKNOWN

Association of Obesity and Cardiovascular Outcomes in Hypertrophic Cardiomyopathy

NCT05645939

Obesity Hypertrophic Cardiomyopathy Cardiovascular Morbidity

UNKNOWN

Association of Obesity and Cardiovascular Outcomes in Patients With Pacemaker

NCT05645978

Pacemaker Complication Arrhythmias, Cardiac Obesity +1 more

UNKNOWN

Association of Obesity and Cardiovascular Outcomes in Dilated Cardiomyopathy

NCT05645952

Dilated Cardiomyopathy Obesity Cardiovascular Morbidity

UNKNOWN

Association of Obesity and Cardiovascular Outcomes in Patients With Implantable Cardioverter-defibrillator (ICD)

NCT05645965

Implantable Defibrillator User Arrhythmias, Cardiac Obesity +1 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This retrospective nationwide cohort study used administrative claims data from the Korean National Health Insurance Service (NHIS) and the combined health check-up database of the National Health Insurance Corporation between 2013 and 2020.

The investigators included oral anticoagulant (OAC) new users diagnosed with atrial fibrillation (AF) between January 2015 and December 2020. Patients aged \<20 years, those who were regarded as valvular AF patients (patients with mitral stenosis or prosthetic heart valve), those with possible alternative indications for OAC (pulmonary embolism, deep vein thrombosis, or recent joint replacement surgery), and those with cancer were excluded from the analysis.

The follow-up period was defined as the time from the index date (date of OAC prescription) to each outcome event, date of death, or end of the study period (December 31, 2020), whichever came first.

Patients' demographic data, comorbidities, concomitant medications, and income level were collected from the Korean NHIS database. The recent health check-up data from the index date was also ascertained, including height, weight, waist circumference, blood pressure, health surveys, and laboratory exam. Health survey included family history, smoking history, alcohol history, and the level of individual physical activity. The investigators defined the proportion of medical use by calculating formula with the recuperation cost and the number of the visit to hospitals.

According to BMI following the World Health Organization recommendation for Asian population, study patients were categorized into 5 groups: underweight, \<18.5 kg/m2; normal range, 18.5 to \<23 kg/m2; overweight, 23 to \<25 kg/m2; obese I, 25 to \<30 kg/m2; and obese II, ≥30 kg/m2\[4\].

During the follow-up period, the investigators assessed 3 clinical outcomes, including thromboembolism, major bleeding, all-cause death, and a composite clinical outcome of thromboembolism+major bleeding+all-cause death. Major bleeding included the brain hemorrhage and gastrointestinal bleeding. Clinical outcomes were mainly defined by the the International Classification of Diseases, 10th revision (ICD-10). Patients were censored at the clinical outcomes, the discontinuation of index OAC treatment, or the end of the study period (December 31, 2020), whichever came first.

Continuous variables are presented as mean±SD or median (interquartile ranges). Categorical variables are presented as numbers and percentages. Baseline characteristics were compared across 5 BMI categories with a linear trend test using a generalized linear model for continuous variables and the Cochran-Armitage trend test for categorical variables. The incidence rates of clinical outcomes were calculated based on the number of events during the follow-up period divided by 100 person-years at risk.

For the primary analyses to evaluate the association between BMI and clinical outcomes in AF patients treated with OAC, the investigators conducted 2 types of analyses: (1) BMI as a continuous variable and (2) BMI as a categorical variable by predefined BMI ranges. First, the association between BMI as a continuous variable (per 5 kg/m2 increase) and clinical outcomes was evaluated using a Cox proportional hazard model to derive unadjusted and adjusted hazard ratios (HRs). Adjusted cubic spline curves were used to visualize the relationship between BMI and the risk of clinical outcomes. Second, the association between different BMI categories and clinical outcomes was explored using adjusted Cox proportional hazard models. Patients with a normal range of BMI defined as 23 to \<25 kg/m2 were used as the reference group. Covariates in the multivariable analysis included age, sex, CHA2DS2-VASc score, comorbidities, renal function, use of antiplatelet agents, and OAC treatment (warfarin or non-vitamin K antagonist OAC \[NOAC\]).

All analyses were 2 tailed, and P\<0.05 was considered significant. Statistical analyses were conducted with R-statistics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Obesity Prognosis Anticoagulants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atrial fibrillation with oral anticoagulant

patients who were newly receiving an oral anticoagulant for atrial fibrillation during study period

Oral anticoagulant

Intervention Type DRUG

Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral anticoagulant

Oral anticoagulant that was continued at least 25days, inculding warfarin and new oral anticoagulant (NOAC)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Oral anticoagulant medication

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Oral anticoagulant (OAC) new users diagnosed with atrial fibrillation (AF) between January 2015 and December 2020

Exclusion Criteria

* Patients aged \<20 years
* Valvular AF patients
* Possible alternative indications for OAC (pulmonary embolism, deep vein thrombosis, or recent joint replacement surgery)
* Cancer patients

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes